Prognosis, staging and treatment of malignant pleural mesothelioma;Prognose, staging und therapie des malignen pleuramesothelioms

Medizinische Klinik

Volumn 97, Issue 8, 2002, Pages 459-471

  Neumeister, Wolfgang ^a   Gillissen, Adrian ^c   Rasche, Kurt ^a   Theile, Anja ^b   Müller, Klaus Michael ^b   Schultze Werninghaus, Gerhard ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Chemotherapy; Gene therapy; Malignant pleural mesothelioma; Multimodality therapy; Photodynamic therapy; Prognostic factors; Radiotherapy; Staging

Indexed keywords

5,6 DIHYDROAZACITIDINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PIRARUBICIN; TRIMETREXATE; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DRUG RESPONSE; GENE THERAPY; HUMAN; MALIGNANT MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; PROGNOSIS; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS; SURGICAL MORTALITY; CLINICAL TRIAL; COMPARATIVE STUDY; MESOTHELIOMA; MORTALITY; PATHOLOGY; PLEURA TUMOR; SURVIVAL RATE;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 0037101818     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-002-1181-5     Document Type: Review

References (127)

1. Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy
2. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Faber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985
3. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma
4. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma
5. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study
6. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies
7. Malignant pleural mesothelioma
8. Phase II trial of mitomycin in malignant mesothelioma
9. Patterns of failure after trimodality therapy for malignant pleural mesothelioma
10. Edatrexate for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B-CALGB 9131
11. Edatrexate with oral leucovorin rescue for malignant mesothelioma: A phase II study of the Cancer and Leukemia Study Group B-CALGB 9131
12. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
13. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma
14. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: A randomized trial of local radiotherapy
15. Pleuropneumectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients
16. Die Therapie des malignen Pleuramesothelioms - Ein fortdauerndes Dilemma
17. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
18. Cisplatin (C) and gemcitabine (G) treatment for malignant mesothelioma: A phase II study
19. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
20. Radiation sensitivity of human lung cancer cell lines
21. Prevalence, diagnosis, and course of mesothelioma
22. Therapeutic modalities in malignant pleural mesothelioma
23. Ranomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
24. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients
25. Effect of interferon-α2a on malignant mesothelioma
26. A prospective study of detorubicin in malignant mesothelioma
27. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma
28. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience
29. Telomerase activity in human pleural mesothelioma
30. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma
31. Response of mesothelioma to large doses of methotrexate CF with rescue (HDMTXCF) used alone or with platinium
32. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems
33. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma
34. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861
35. Potential for cytokine therapy of malignant mesothelioma
36. Thoracic surgical problems in asbestos-related disorders
37. Radiation in the management of patients with mesothelioma
38. Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma
39. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients
40. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
41. Malignant pleural mesothelioma
42. Malignant pleural mesothelioma in western Glasgow 1980-1986
43. Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital
44. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy
45. Two dose levels of ifosfamide in malignant mesothelioma
46. Aspects of histopathologic subtypes as a prognostic factor in 85 pleural mesotheliomas
47. A phase II study of pirarubicin in malignant pleural mesothelioma
48. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B
49. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
50. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients
51. Management of malignant pleural mesothelioma: A critical review
52. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The UCLA experience
53. Statistical contributions to phase II trials in cancer: Interpretation, analysis and design
54. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses
55. Diffuse, mixed malignant pleural mesothelioma
56. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: A nonrandomized phase II study
57. Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma
58. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma
59. Treatment of malignant mesothelioma with epirubicin and ifosfamide: A phase II cooperative study
60. Phase II trial of topotecan for the treatment of mesothelioma
61. Anti-sense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo
62. Natural history and clinical staging of malignant mesothelioma
63. Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
64. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma
65. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma
66. Good symptom relief with palliative MVP (mitomyycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma
67. Gemcitabine for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9530)
68. Phase II trial of high dose cisplatin in patients with malignant mesothelioma
69. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
70. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma
71. Chemotherapy in malignant pleural mesothelioma. A review
72. Photodynamic therapy for thoracic malignancies
73. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
74. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma
75. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction
76. The proposed new international TNM staging system for malignant pleural mesothelioma: Application to imaging
77. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma
78. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: A phase II study
79. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma
80. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma
81. Phase II trial of carboplatin in the management of malignant mesothelioma
82. Aggressive multimodality therapy for malignant pleural mesothelioma
83. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients
84. A proposed new international TNM staging system for malignant pleural mesothelioma
85. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma
86. The role of extrapleural pneumectomy in malignant pleural mesothelioma: A Lung Cancer Study Group trial
87. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma
88. The importance of surgical staging in the treatment of malignant pleural mesothelioma
89. A review of chemotherapy trials for malignant mesothelioma
90. Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC Lung Cancer Cooperative Group
91. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B
92. Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation
93. Treatment strategy in pleural mesothelioma
94. Chirurgische therapien der primären und sekundären pleuratumoren
95. Photodynamic therapy for malignant mesothelioma: Preclinical studies for optimization of treatment protocols
96. Immunotherapy-based treatment strategies for malignant mesothelioma
97. The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study
98. Treatment of a patient with malignant mesothelioma with interferon-α2 based on in vitro sensitivity tests
99. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma
100. Augmentation of activity of cis-diamminedichloroplatinum (II) and mitomycin-c by interferon in human mesothelioma xenografts in nude mice
101. Highdose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
102. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma
103. Combined sytemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a
104. Advances in the treatment of malignant pleural mesothelioma
105. High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: Report of four cases
106. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma
107. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
108. Multimodality therapy for malignant pleural mesothelioma
109. Multimodality management of malignant pleural mesothelioma
110. Intracavitary photodynamic therapy for malignant pleural mesothelioma
111. Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: A phase II study
112. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: An assessment in 88 patients
113. Oral etoposide in the treatment of malignant mesothelioma. A phase II study
114. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon
115. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma
116. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma
117. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: A phase I trial (BB-IND 6274)
118. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma
119. Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study
120. Gemcitabine in malignant mesothelioma
121. A phase II study of gemcitabine in patients with malignant pleural mesothelioma
122. Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B
123. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity
124. Trimexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II Study
125. Pleural mesothelioma
126. Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases
127. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma